Usefulness of Lactococcus lactis Strain Plasma for Treatment of Allergic Rhinitis: Four Case Reports
Abstract
Allergic rhinitis affects many people, especially due to cedar and cypress pollen in spring, for which no effective, reliable, and decisive treatment has been established. Recently, Lactococcus lactis strain Plasma, which exhibits immunostimulatory effects and regulates plasmacytoid dendritic cells, has attracted much attention. In this study, we investigated whether Lactococcus lactis strain Plasma would be effective against allergic rhinitis. To examine the possible effects, we had 4 volunteer rhinitis patients with allergies to Japanese cedar and cypress who took a drink or
supplement containing 100 billion lactobacilli during the pollen season and throughout the year over the 2022 and 2023 seasons. In the 2022 season, 3 patients with mild-to-moderate symptoms no longer required anti-allergic medications. However, 2 required an anti-allergy drug in 2023, and the amount of pollen reportedly scattered was large, even though they took it year-round. The other 2 patients who had been taking Lactococcus lactis strain Plasma for the entire year or throughout the pollen season had almost no symptoms. These results suggest that Lactococcus lactis
strain Plasma could have an auxiliary effect in controlling rhinitis, regardless of the amount of scattered pollen and the patient’s immune responsiveness.
References
- Meng Y, Wang C, Zhang L. Advances and novel developments in allergic rhinitis. Allergy. 2020;75(12):3069-3076.
- Osada T, Okano M. Japanese cedar and cypress pollinosis updated: new allergens, cross-reactivity, and treatment. Allergol Int. 2021;70(3):281-290.
- May JR, Dolen WK. Management of allergic rhinitis: a review for the community pharmacist. Clin Ther. 2017;39(12):2410-2419.
- Jounai K, Sugimura T, Morita Y, Ohshio K, Fujiwara D. Administration of Lactococcus lactis strain Plasma induces maturation of plasmacytoid dendritic cells and protection from rotavirus infection in suckling mice. Int Immunopharmacol. 2018;56:205-211.
- Peng YQ, Qin ZL, Fang SB, et al. Effects of myeloid and plasmacytoid dendritic cells on ILC2s in patients with allergic rhinitis. J Allergy Clin Immunol. 2020;145(3):855-867.e8.
- Horiuchi Y. Seasonal facial erythema in a patient with allergic rhinitis treated using a combination of tranilast and Roxithromycin. Immunopharmacol Immunotoxicol. 2022;45:1-3.
- Suzuki H, Jounai K, Ohshio K, Fujii T, Fujiwara D. Administration of plasmacytoid dendritic cell-stimulative lactic acid bacteria enhances antigen-specific immune responses. Biochem Biophys Res Commun. 2018;503(3):1315-1321.
Details
| Primary Language | English |
|---|---|
| Subjects | Allergy, Otorhinolaryngology |
| Journal Section | Case Report |
| Authors | |
| Publication Date | August 28, 2023 |
| Published in Issue | Year 2023 Volume: 6 Issue: 2 |
Cite
You can find the current version of the Instructions to Authors at: https://www.eurjrhinol.org/en/instructions-to-authors-104
Starting on 2020, all content published in the journal is licensed under the Creative Commons Attribution-NonCommercial (CC BY-NC) 4.0 International
License which allows third parties to use the content for non-commercial purposes as long as they give credit to the original work. This license
allows for the content to be shared and adapted for non-commercial purposes, promoting the dissemination and use of the research published in
the journal.
The content published before 2020 was licensed under a traditional copyright, but the archive is still available for free access.